| Background:Coronary atherosclerotic heart disease (CAD) is a common disease and one of principal causes of illness and death. This disease often begins in 40 years of age. The incremental risk for CAD is greater in developed countries of Europe and America, and also in men. About 500 thousand people in the United States die from it each year, accounting for 1/3～1/2 of total deaths and 50%～75% of heart disease deaths, In recent years, the morbility and mortality of CAD in China are increasing year by year. Until the 1990s', the mortality rate of CAD in China are 49.2/100 thousand people in urban men and 32.2/100 thousand in women. With the development of percutaneous coronary intervention (PCI), PCI becomes a extensive method of clinical treatments and has made significant and positive clinical results.But coronary microembolization is a significant and frequent complication of primary percutaneous coronary intervention in the patients. More importantly, coronary microembolization is a main reason of dysfunction of microcirculation. The incidence of myocardial injury after PCI is about 10% to 40%, with the level of myocardial damage makers increasing. Shexiangbaoxin pill contains musk, ginseng extract, bezoar, cassia bark, storax, dried toads venom and borneol. People use it as a treatment for CAD for many years, particularly as traditional Chinese medicine to alleviate angina pectoris with a fast and precise effect. Now, with the provement of many basic researches and clinical practices, people find that it has the effects of therapeutic angiogenesis, vascular protection, reducing infarct size, prevention of ventricular remodeling, regulating blood lipids and inhibition of vascular inflammatory response. Past studies confirmed using atorvastatin, trimetazidine or Xuezhikang before PCI can significantly reduce the incidence of myocardial lesion, but about the effect of high-dose of Shexiangbaoxin pill on myocardial lesion after PCI has not been reported.Objective:To evaluate the effect of high-dose of Shexiangbaoxin Pill on myocardial lesion after Percutaneous Coronary Intervention (PCI).Methods:We studied more than 600 hospitalized patients with unstable angina(UA) who would undergo coronary angiography (CAG) and had normal cardiac troponin I (cTnI) and creatine kinase-MB isoenzyme(CK-MB) before operation in cardiovascular department of Changhai Hospital from December 2008 to January 2010. They were randomly divided into control group and experimental group. All of the patients received ordinary therapy, and patients in experimental group were received high-dose of Shexiangbaoxin Pill for 3 days before PCI. After PCI, we chose 133 patients of them who underwent PCI and met the inclusion criteria. Serum levels of cTnI and CK-MB were detected by electrochemiluminescence method and enzyme activity inhibition assay before, 12 and 24 hours after PCI, respectively. The occurrence of cardiac events was recorded and compared between two groups in a 30 d follow up.Results:There was significant difference between control group and experimental group on the serum level of cTnI in 12 and 24 h after PCI(P<0.01, P<0.05). The incidence of cTnI>3×ULN was 13.64% in the experimental group and 28.36% in the control group (P<0.05).The cases of cardiovascular events were lower in experimental group compared with control group, but the difference was not statistically significant (P>0.05).Conclusion:Shexiangbaoxin Pill may reduce the cTnI level after PCI and has a protective effect against myocardial lesion induced by PCI.
|
PDF Full Text Request